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Abstract 
Human papillomavirus (HPV) causes oropharyngeal squamous cell carcinoma (OPSCC), although 
strongly divergent results have been reported regarding the prevalence of HPV16 in different 
countries, whether this represents important differences in etiology remains unclear. Applying 
rigorous protocols for sample processing, we centrally evaluated 1,420 head and neck tumors (533 
oropharynx, 395 oral cavity and 482 larynx) from studies conducted in the US, Europe and Brazil 
for mucosal HPV DNA and p16INK4a expression to evaluate regional heterogeneity in the proportion 
of HPV16‐associated OPSCC and other head and neck cancer, and to assess covariates associated 
with the risk of HPV16‐positive OPSCC. While majority of OPSCC in the US (60%) were HPV16‐
positive, this proportion was 31% in Europe and only 4% in Brazil (p < 0.01). Similar differences 
were observed for other head and neck tumors, ranging from 7% in the US and 5% in Europe, to 
0% in South America. The odds of HPV16‐positive OPSCC declined with increasing pack years of 
smoking (OR: 0.75; 95% CI: 0.64–0.87) and drink years of alcohol use (OR: 0.64; 95% CI: 0.54–
0.76). These results suggest that while the contribution of HPV16 is substantial for the oropharynx, 
it remains limited for oral cavity and laryngeal cancers.  
Head and neck cancers (HNC) contribute nearly 600,000 new cases diagnosed, and over 300,000 
deaths1 each year. Alongside traditional risk factors such as smoking and excessive alcohol 
consumption,2, 3 human papillomavirus type 16 (HPV16) infection has been recognized to cause a 
subset of these cancers.4, 5 
Strongly divergent results have been reported regarding the extent of HPV16 infection in HNC in 
different countries.6-8 Studies in the US suggest that the majority of oropharyngeal squamous cell 
carcinoma (OPSCC) are now caused by HPV16,9-11 although proportions of <10% have been 
reported in the few studies completed in South America,12-14 with European estimates being in 
between.15-17 Further, the role of HPV16 in HNC outside the oropharynx remains unclear.8 A 
recent review has estimated that the probability of an HPV‐attributable cancer of the oral cavity, 
larynx and hypopharynx could be up to five times lower than that of oropharyngeal cancer.18 
Whether these divergent geographic results represent important differences in the etiology of HNC 
or whether they are explained by differences in laboratory practices is unknown. The recent 
publication on global HPV prevalence in HNC is of note where, based on a comparison of over 
3,000 tumors tested for HPV DNA and subsequently, following triage for HPV16 E6*mRNA and 
p16INK4a, the authors report that nearly 22% of OPSCC could be attributed to HPV infection, while 
fewer than 5% of oral cavity and laryngeal cancers were HPV‐positive.19 The study also reported 
strongly divergent results for the South and Central America (OPSCC HPV prevalence of 37%), 
and did not provide estimates for North America. Although the largest study to date, this report was 
unable to explore lifestyle factors associated with HPV‐positivity.  
We centrally tested a large series of HNCs from three different continents using a combination of 
HPV16 DNA detection and p16INK4a expression, our aims were to (i) evaluate regional 
heterogeneity in the proportion of HPV16‐associated OPSCC and other HNC following rigorous 
protocols of sample processing; and (ii) evaluate covariates associated with the risk of HPV16‐
positive OPSCC.  
Methods 
The study was designed to include at least 400 HNCs, including 110 OPSCCs, from three HNC 
case‐control studies conducted in the US, Europe and Brazil. All tumors were histologically 
confirmed diagnoses, and squamous cell in origin. HNC included cancers arising at the oral cavity 
(International Classification of Diseases for Oncology [ICD‐O] C00.3–C00.9, C02.0–C06.9, C14.0‐
C14.9, excluding C02.4, C05.1, C05.2), oropharynx (ICD‐O: C01, C02.4, C09, C10), hypopharynx 
and larynx (ICD‐O: C13, C32), and non‐specified and overlapping sites (ICD‐O: C05.1‐C05.2, 
C14.0, C014.2, C014.8). 
The Carolina Head and Neck Cancer (CHANCE, NC) study recruited population‐based incident 
HNCs and matched controls between 2002 and 2006.20 This analysis included 477 tumors 
comprising 123 oral cavity, 243 oropharynx, 107 laryngeal and 4 tumors of overlapping sites. The 
European Alcohol Related Cancers and Genetic susceptibility in Europe (ARCAGE) study was 
conducted across 10 countries in Europe.21 Tumor samples from 539 HNCs from Germany 
(n = 181), Italy (n = 289) and the UK (n = 69) were included that consisted of 165 oral cavity, 119 
oropharynx, 251 larynx and 4 cancers of overlapping sites. The Brazilian Head and Neck Genome 
Project (GENCAPO, São Paulo, Brazil) study recruited incident HNC patients and matched controls 
during 2002 to 2015.22, 23 Four hundred and four HNCs included 107 oral cavity, 171 
oropharyngeal, 124 larynx and two cancers of overlapping sites. Risk factor and lifestyle data were 
combined; briefly, tobacco use was categorized as ever or never smokers; ever smokers were 
defined as individuals who smoked any tobacco product (US), at least once a week for a year 
(Europe), or daily for a year (Brazil). Pack years were calculated for all types of tobacco smoking 
based on cigarette equivalents, where one cigar equaled five cigarettes, one pipe equaled four 
cigarettes and one hand‐rolled cigarette equaled five store‐bought cigarettes (Brazil only). Ever 
drinkers were those who reported ever consumption of any alcoholic beverage (US and Europe) or 
at least once a month (Brazil). A drink‐year was defined as two drinks per week for 1 year, where a 
drink equaled 330 mL of beer, 125 mL of wine and 50 mL of liquor.  
A tumor sectioning protocol was established as described previously24 that was applied to tumors 
from Brazil and Europe, while in the US, pre‐sectioned slides generated using a similar scheme 
were available and included. All tumors were subjected to pathology assessment completed 
centrally at IARC. Briefly, pathology evaluation determined 3.7% of all cases as ineligible due to 
insufficient tumor tissue or necrotic tissue, of which 0.8% were from the US, 5.4% from Europe and 
4.4% from Brazil. The p16INK4a expression was evaluated using the CINtec Histology P16INK4a Kit 
(9511, mtmlabs) following manufacturer's instructions. Staining and scoring was performed blinded 
with respect to tumor subsite and HPV DNA status. Expression was scored based on the percentage 
and intensity of nuclear and/or cytoplasmic staining, a composite score of 4 or greater was 
considered positive for p16INK4a overexpression.25 However, the proportion of p16 invalid tumors 
was under 1% and did not vary by study. DNA was extracted from tumor tissues26 and HPV 
genotyping was performed using the Type‐Specific E7 PCR bead‐based multiplex assay (TS‐E7‐
MPG, IARC, Lyon, France).27-29 Briefly, reporter fluorescence was quantified using Luminex 
reader 200 (Luminex Corporation, Austin, TX) and cutoffs were computed by adding 5 to 1.1 × the 
median background value expressed as median fluorescence intensity (MFI). HPV16, HPV18, 
HPV31, HPV33, HPV35, HPV39, HPV58, HPV59 were considered carcinogenic.5, 30 Since 
HPV16 accounts for over 95% of all HPV‐positive HNC,8, 12, 31, 32 the main results described in 
this manuscript are focused on this type. The largest proportion of betaglobin negative samples 
were noted in the Brazilian study (14%), compared to the US (2.4%) or European studies (4.6%). 
We further included several quality indicators at each stage of HPV testing including: (i) sectioning 
empty paraffin block every 10 tumors, (ii) one DNA extraction control per batch, (iii) one PCR 
control per amplification plate, (iv) one negative water hybridisation control per batch and (v) 
randomly selected tumors for retesting from each of the three studies (∼5%). HPV testing was 
completed centrally at the International Agency for Research on Cancer (IARC). Twenty nine of 
188 empty paraffin sections yielded a positive result for the betaglobin control gene (all were HPV 
DNA negative) reflecting a contamination rate of 15%. None of the other technical controls were 
positive for either the beta globin or HPV DNA. Among the 208 HNCs randomly retested, 8 tumors 
(3 each from Brazil and Europe and 2 from the US) were discordant for either HPV DNA (n = 6, 4 
for HPV16 DNA) or betaglobin status (n = 2). The discordance rate in the duplicate testing was 
under 4%, and did not vary by region.  
Characteristics of cases were compared using Pearson's chi‐squared statistic for categorical and 
Kruskal‐Wallis test for continuous variables. The primary outcome was HPV16‐positive tumors 
defined as being HPV16 DNA and P16INK4a‐positive, with cases that were HPV16 DNA or 
P16INK4A‐negative considered HPV16‐negative. Unconditional logistic regression was used to 
estimate odds ratios (OR) and corresponding 95% confidence intervals (95% CI) of HPV16‐positive 
OPSCC using covariates of age, sex, education level, stage, region, smoking (10 pack‐year 
intervals) and alcohol consumption (10 drink‐year intervals). The incidence rates of HPV16‐
positive and ‐negative OPSCC and Non‐OPSCC were estimated by multiplying the incidence rate 
per 100,000 with the corresponding HPV16 prevalence observed in the present study. All statistical 
analyses were performed using STATA statistical software, version 11 (StataCorp, College Station, 
TX), and all reported p values are two sided. Statistical significance was set at p less than 0.05.  
Results 
This analysis included 1,420 HNCs, including 477 from the US, 539 from Europe and 404 from 
Brazil (Table 1). European subjects were only marginally older (median age of 60) than the US 
(median age = 56) and Brazilian subjects (median ages= 57; p < 0.01), current smoking and drinking 
were high in all three regions. More than two thirds of the HNC cases were diagnosed at late stages 
of the disease in Brazil (69% stage IV) compared to the less than half of cases in the US and Europe 
(∼47% stage IV).  
Table 1. Description of the study group  
Description 
 
US Europe  Brazil Total
N cases  477 539  404 1,420
   
N (%)  N (%)  N (%) N (%)
Years of diagnosis  2002–2006 2002–2005  2002–2011
 
Age  IQR  64–50 68–54  64–50 66–51
(in years)  Median  56  60  57  58
Sex  Men  365 (76.5)  426 (79.0)  356 (88.1) 1,147 (80.8)
 
Women  112 (23.5)  113 (21.0)  48 (11.9) 273 (19.2)
Education  ≤Primary school  144 (30.2)  222 (46.5)  314 (77.9) 680 (50.1)
levela  Secondary school  142 (29.8)  219 (45.8)  61 (15.1) 422 (31.1)
 
Any college  191 (40.0)  37 (7.7)  88 (7.0) 256 (18.8)
Raceb  Caucasian  346 (72.5)  539 (100.0)  290 (72.5) 1,175 (83.0)
 
Black  120 (25.2)  0  39 (9.7) 159 (11.2)
 
Asian  5 (1.1) 0  3 (0.8) 8 (0.6)
 
Mixed  2 (0.4) 0  64 (16.0) 66 (4.6)
 
Other  4 (0.8) 0  4 (1.0) 8 (0.6)
Smokingc  Never  58 (12.2)  55 (10.2)  11 (2.7) 124 (8.8)
 
Former  129 (27.2)  173 (32.2)  89 (22.2) 391 (27.7)
 
Current  288 (60.6)  310 (57.6)  301 (75.1) 899 (63.6)
Median pack years  43.0  39.0  43.7
 
Alcohold  Never  46 (9.7) 43 (8.1)  42 (10.5) 131 (9.3)
 
Former  149 (31.3)  63 (11.9)  163 (40.7) 375 (26.7)
 
Current  281 (59.0)  423 (80.0)  196 (48.9) 900 (64.0)
Median drink years  49.6  23.3  100.3
 
Description 
 
US Europe  Brazil Total
N cases  477 539  404 1,420
   
N (%)  N (%)  N (%) N (%)
Stagee  I  70 (15.3)  69 (16.9)  18 (4.5) 157 (12.4)
 
II  80 (17.5)  71 (17.4)  49 (12.3) 200 (15.8)
 
III  89 (19.5)  77 (18.8)  57 (14.4) 223 (17.7)
 
IV  218 (47.7)  192 (46.9)  273 (68.8) 683 (54.1)
Cancer site  Oral cavity  123 (25.8)  165 (30.6)  107 (26.5) 395 (27.8)
 
Oropharynx  243 (50.9)  119 (22.1)  171 (42.3) 533 (37.5)
 
Larynxf  107 (22.4)  251 (46.6)  124 (30.7) 482 (33.9)
 
Overlappingg  4 (0.8) 4 (0.7)  2 (0.5) 10 (0.7)
 a 62 cases missing education information; 61 from Europe, 1 case from Brazil.  
 b Missing information for 4 cases (Brazil).  
 c Data missing for 6 cases (2 each from the US,1 from Europe and 3 from Brazil). Median estimated among ever smokers.  
 d Data missing for 14 cases (1 US, 10 Europe, 3 from Brazil). Median estimated among ever alcohol users.  
 e Missing for 130 cases from Europe, 20 from the US and 7 from Brazil.  
 f Includes hypopharynx and larynx cases.  
 g Includes cancers of overlapping sites and non‐specified sites.  
Majority of the tumors were positive for a single HPV type (∼95%), with HPV16 DNA 
contributing 92% of all HPV DNA positivity (Supporting Information Table 1), and HPV35 (3.5%), 
HPV18 (2.7%) and HPV33 (1.5%) were also observed. The proportion of HPV16‐positive OPSCC 
differed dramatically by continent, US had the highest proportion (59.3%), Brazil the lowest 
(4.1%), and Europe reflected intermediate HPV16 prevalence (31.1%; Table 2). The proportion of 
HPV16‐positive tumors did not vary among the three European countries. Regarding oral cavity 
cancer, 10.6% of tumors in the US and 6.1% in Europe were HPV16‐positive (p = 0.20), whereas 
2.8% of larynx tumors in the US and 5.2% in Europe were HPV16‐positive (p = 0.30). None of the 
231 oral or larynx cancer cases in Brazil were HPV16‐positive. In order to clarify whether subsite 
misclassification could contribute to some HPV16‐positive oral cavity cancers, we reassessed the 
sub‐anatomic classification of these tumors based on ICD‐O codes. Twelve of the 23 HPV16‐
positive oral cavity tumors were lesions overlapping the tongue, HPV16 prevalence when excluding 
these was 2.8% (95% CI: 1.19–5.55). When we examined the marginal incidence of HPV16‐
positive OPSCC, similar results were observed; the highest incidence of HPV‐positive OPC were 
reflected in the US (2 per 100,000), followed by Europe (∼1 per 100,000) and the least in Brazil 
(∼0.2 per 100,000). Similarly, HPV16‐positive non‐OPSCC incident fraction was consistently 
under 1% in the US and Europe, while it was 0% in Brazil.  
Table 2. Prevalence of HPV16‐related cancera: by region  
Region 
Cancer Site Overallb US Europe Brazil 
 N 
Prevalence% (95% 
CI) N
Prevalence% (95% 
CI) N
Prevalence% (95% 
CI) N 
Prevalence% (95% 
CI) 
Region 
Cancer Site Overallb US Europe Brazil 
 N 
Prevalence% (95% 
CI) N
Prevalence% (95% 
CI) N
Prevalence% (95% 
CI) N 
Prevalence% (95% 
CI) 
Oropharyngeal cancerc 533 35.3 (31.2–39.3) 243 59.3 (53.1–65.5) 119 31.1 (22.7–39.5) 171 4.1 (1.1–7.1) 
Non‐oropharyngeal 
cancers 887 4.4 (3.0–5.7) 234 6.8 (3.6–10.1) 420 5.5 (3.3–7.7) 233 0 
Oral cavity4 395 5.8 (3.5–8.1) 123 10.6 (5.1–16.0) 165 6.1 (2.4–9.7) 107 0 
Larynx/hypopharynxd 482 3.3 (1.7–4.9) 107 2.8 (0.0–6.0) 251 5.2 (2.4–7.9) 124 0 
 a defined as joint positivity to HPV16 DNA and p16INK4a overexpression.  
 b None of the 10 tumors of overlapping sites were HPV16‐positive.  
 c Chi‐squared p values for the difference in prevalence between the three regions was <0.01.  
 ‐squared p values for the difference in prevalence between the US and Europe was 0.20, US and Brazil: <0.01 and Europe and Brazil was 
0.01.  
 d Chi‐squared p values for the difference in prevalence between the US and Europe or Brazil was >0.10, Europe and Brazil was 0.01.  
Regarding the discordance between p16INK4a and HPV16 DNA, there were 10.1% OPSCC (n = 54) 
and 14.5% non‐OPSCC tumors (n = 127) that were p16INK4a‐positive but HPV16 DNA negative 
with no regional difference (p > 0.20) (Supporting Information Table 2). Similarly, 9.8% of OPSCC 
and 14.5% of non‐OPSCC were p16INK4a‐negative but HPV16 DNA‐positive. The highest 
proportion was observed in Europe compared to US and Brazil (p < 0.01). Concurrent 
overexpression of P16INK4a with oncogenic HPV types other HPV16 was rare (14 of 4,120, <1%), 
nearly all were from the US and were more often observed in OPSCC (11/529) compared to the oral 
cavity or larynx (3/887) (Supporting Information Table 3).  
In multivariable analyses, the odds of being a HPV16‐positive OPSCC was significantly associated 
with college education level (OR (95%CI): 3.60 (1.77–7.30)), pack years of ever smoking (OR: 
0.75; 95% CI: 0.64–0.87), drink years of ever alcohol use (OR: 0.64; 95% CI: 0.54–0.76), and 
geographic region (Europe vs. US: OR = 0.42; 95% CI: 0.22–0.82; Brazil vs. US: OR: 0.04; 95% 
CI: 0.01–0.09; Table 3). Similar results were observed in univariable analysis (Supporting 
Information Table 4). We observed that ever smokers were less likely to be HPV16‐positive (OR: 
0.09; 95% CI: 0.04–0.18, Supporting Information Table 4), and the prevalence of HPV16 declined 
with increasing pack years (Supporting Information Table 5), similar results were noted for alcohol 
use. The observed inverse associations with smoking and alcohol were robust across geographic 
regions (p‐heterogeneity: 0.10 and 0.66, respectively), while education was only significant in the 
US.  
Table 3. Multivariable factors associated with HPV16‐positive oropharyngeal cancer  
Overall (N = 533) US (N = 243) Europe (N = 119) Brazil (N = 171) 
Risk factor N % HPV16 positiveb OR (95% CI)c OR (95% CI)c OR (95% CI)c OR (95% CI)c p‐heterogeneitya
Age 
(10 year increase) 
533 – 0.95 (0.71–1.27) 0.75 (0.49–1.16) 0.98 (0.53–1.81) 1.21 (0.39–3.78) 0.64 
Sex 
Men 447 33.8 1.0 1.0 1.0 1.0 
Women 86 43.0 0.56 (0.27–1.15) 0.65 (0.22–1.96) 0.34 (0.07–1.68) 0.42 (0.02–8.19) 0.79 
Education level 
≤Primary school 252 15.9 1.0 1.0 1.0 1.0 
Secondary school 144 40.3 2.31 (1.23–4.35) 2.68 (0.88–8.13) 1.76 (0.54–5.72) 17.59 (0.56–555.11) 0.45 
Any college 131 67.9 3.60 (1.77–7.30) 2.23 (0.82–6.06) 0.29 (0.01–7.69) 25.24 (0.45–1,410.25) 0.24 
Race 
Caucasian – – – 1.0 – – 
Black – – – 0.04 (0.01–0.13) – – 
Mixed – – – 0.15 (0.01–3.16) – – 
Overall (N = 533) US (N = 243) Europe (N = 119) Brazil (N = 171) 
Risk factor N % HPV16 positiveb OR (95% CI)c OR (95% CI)c OR (95% CI)c OR (95% CI)c p‐heterogeneitya
Lifetime sex partners 
0–3 – – – 1.0 – – 
4–5 – – – 4.21 (1.36–13.0) – – 
Staged 
I 25 32.0 1.0 1.0 1.0 1.0 
II 44 27.3 0.79 (0.20–3.11) 0.91 (0.16–5.25) – – 
III 35 39.8 1.62 (0.49–5.32) 1.93 (0.38–9.77) 1.21 (0.11–13.78) – 0.75 
IV 120 35.7 2.49 (0.83–7.45) 1.73 (0.41–7.37) 3.20 (0.35–28.89) – 0.65 
Smoking status 
Never 57 82.5 1.0 1.0 1.0 1.0 
Pack yearse 472 29.8 0.75 (0.64–0.87) 0.84 (0.66–1.06) 0.59 (0.41–0.84) 0.36 (0.13–0.99) 0.10 
Alcohol status 
Never 39 53.8 1.0 1.0 1.0 1.0 
Drink yearse 478 33.9 0.64 (0.54–0.76) 0.64 (0.48–0.84) 0.62 (0.44–0.87) 0.40 (0.15–1.05) 0.66 
Region 
US 243 59.3 1.0 – – – 
Europe 119 31.1 0.42 (0.22–0.82) – – – 
Brazil 171 4.1 0.04 (0.01–0.09) – – – 
 a chi‐squared test for heterogeneity across the studies.  
 b HPV16 positivity was define as tumor positive for HPV16 DNA and overexpressing P16INK4a protein.  
 c Estimates were adjusted for age, sex, education level, stage, region, smoking (10 pack year intervals) and alcohol consumption (10 drink 
year intervals) as appropriate.  
 d Seven HPV16 positives in Brazil were all of advanced stage.  
 e Denotes increments of 10 pack years or drink years until 40 or more as appropriate.  
Discussion 
In this study of 1,420 HNCs from three world regions, we demonstrate dramatic differences in the 
prevalence of HPV16‐positive HNC. While nearly 60% of OPSCCs in the US are HPV16‐positive, 
this proportion is only about 4% in Brazil, and OPSCCs in Europe have intermediate HPV16 
prevalence (31%). <4% of laryngeal and oral cavity cancers are HPV16‐positive. That similar 
results were noted for the marginal incident fractions of HPV16‐positive OPSCC and non‐OPSCC 
lends support to these conclusions. 
We show that among OPSCC cases, ever smokers and ever drinkers are less likely to be HPV16‐
positive, and the prevalence of HPV16‐positive OPSCC declines with increasing pack years of 
smoking and drink years of alcohol use. It is noteworthy that these conclusions are based on case 
comparisons, therefore, a higher HPV attributable fraction is expected among never 
smokers/drinkers as these individuals developed the disease in the absence of the most common risk 
factors‐ smoking and alcohol. It also remains to be noted that these results do not represent 
incidence rate interpretations. 
Our results are consistent with the few studies that have examined both HPV DNA and p16INK4a 
expression in OPSCC, both for estimates in the US.32-34 as well as Europe.15-17, 35 Fewer studies 
have been reported from South America, our observations are similar to the earlier report describing 
HPV16 prevalence in OPSCC as 4.4%.14 In this context, the recent pooled analysis on HPV 
prevalence in HNC is of note where, based on 158 tumors from South and Central America tested 
for HPV DNA and subsequently, following triage for HPV16 E6*mRNA and p16INK4a, the authors 
report a prevalence of 37% for HPV‐positive OPSCC.19 Our estimates are substantially lower than 
this report even though the number of OPSCC included is comparable. Similarly, our estimates for 
HPV16‐positive OPSCC in Europe are higher than the reported 16%. It is possible that these 
differences could reflect distinct geographic locations of sampling; while majority of the tumors in 
the published pooled analysis were drawn from southern Europe, nearly 70% of our European 
OPSCC subjects were from western and northern Europe. Similarly, South and Central America 
were represented by nine countries of the region (Argentina, Chile, Colombia, Ecuador, Guatemala, 
Honduras, Mexico, Paraguay and Venezuela), it is noteworthy that Brazil was not among these. It is 
also possible that the differences could be due to differing periods of sampling, the pooled analysis 
retrieved tumors diagnosed over a longer period (1990–2012), with almost 60% of the cases 
diagnosed after 2005 while most OPSCC tumors included in this analysis were recruited before 
2005. Our study consistently showed that a low proportion (∼4%) of non‐OPSCC were HPV‐
positive across all three continents. A marginally higher proportion of HPV16‐positive tumors were 
observed in the oral cavity (5.8%) compared to the larynx (3.3%). Closer inspection of the 
subanatomic sites revealed that almost half all the HPV16‐positive oral cavity tumors may have 
been potentially misclassified and suggest that the true prevalence of HPV16 in oral cavity cancer is 
likely to be much lower (∼3%), and similar to that of laryngeal tumors.  
The comparison of a large number of tumors tested for HPV16 DNA and p16INK4a shows that the 
methods are discordant in 8–13% of the cases. The lack of specificity of p16INK4a appears to vary by 
subsite but not by region and the specificity of p16INK4a outside the OPSCC appears to be low.18, 
36, 37 Some authors have suggested the use of p16INK4a testing as replacement for HPV DNA,38, 
39 however, our results argue against this approach. For oncogenic HPV types other than HPV16, 
concurrent P16INK4A expression occurred more often in OPSCC compared to other HNC sites. 
Whether this reflects oncogenicity awaits further functional data.  
Geographic differences in the proportion of HPV16‐positive OPSCC may in part be explained by 
differences in tobacco use (i.e. the varying proportion of smoking‐related OPC in each region). This 
hypothesis is supported by higher age‐standardized incidence rates of OPSCC in Brazil (ASRSão 
Paulo: 4.0) compared to other regions (ASRNorth Carolina, US: 3.4 and ASRGermany, Italy, Scotland: 2.4).40 
However, data on smoking prevalence in the general population of these regions does not provide 
clear support. While tobacco smoking was lower among controls in the US study compared to 
Europe (median smoking pack‐years: 6.5 and 7.6 in US and Europe), Brazil had the lowest smoking 
prevalence (median smoking pack‐years: 2.6), suggesting the differences in tobacco use do not fully 
explain the observed HPV prevalence differences in OPSCC. As performing oral sex is the primary 
risk factor for HPV‐positive OPSCC, differences in oral sexual behavior likely contribute to 
differences in incidence, but unfortunately sexual data was not available in two of the studies. It is 
important to note however that these risk factors are subject to strong birth cohort effects. In 
addition, smoking and alcohol are additionally impacted by strong interaction effects.  
Despite the dramatic differences in HPV prevalence, the three studies were similar in terms of the 
risk factor profiles, which was reflected in the consistency of the factors associated with HPV‐
positivity. The limitations of our study arise from utilizing previously collected survey data from 
studies that did not collect identical lifestyle data. For instance, sexual behavior questions were not 
included in the European and South American study, while the data collected in the US study was 
limited. In addition, although we present results for three world regions, it must be noted that the 
US is represented by a single study conducted in North Carolina where smoking prevalence is 
among the highest in the country. Similarly, Europe is represented by three countries only while 
South America is represented by a single study that was conducted in Brazil with all cases being 
recruited from public hospitals in São Paulo. 
We conclude that the proportion of OPSCC now caused by HPV16 varies by geographic region 
with low proportions in Brazil, moderate proportions in Western Europe, and the majority of 
OPSCC diagnosed in the US being HPV16‐positive. Our results suggest that the effect of 
prophylactic HPV vaccination on OPSCC would be largest in the US. 
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